Elritercept
TAK-226-3001
Phase 3 small_molecule active
Quick answer
Elritercept for Myelodysplastic Syndrome is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Myelodysplastic Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active